Evidence map›Paper›PMID 42653002›Full record

ArticleLife (Basel, Switzerland)2026

Integrated Chemical, Computational, and Cellular Profiling of a Dual-Oil Melanoma Formulation: An Exploratory Life-Science Study.

Katarina Dunjic, Momir Dunjic, Marina Gazdic Jankovic, Marina Miletic Kovacevic, Nikolina Kastratovic, Biljana Ljujic, Tatjana Novakovic, Milan Filipovic, Tatjana Filipovic, Zhao Jing and 6 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Katarina DunjicDiscipline of Dermato-Venereology, Quince Medic Clinic, Bulevar Oslobodjenja 2, 11000 Belgrade, Serbia.
Momir DunjicDiscipline of Obstetrics/Gynecology and Integrative Medicine, Faculty of Medicine, University of Pristina, Anri Dinana bb, 38220 Kosovska Mitrovica, Serbia.ORCID 0000-0002-8594-0135
Marina Gazdic JankovicDepartment of Genetics, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0001-8151-9004
Marina Miletic KovacevicDepartment of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-5177-1521
Nikolina KastratovicDepartment of Genetics, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-7238-7414
Biljana LjujicDepartment of Genetics, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-6759-2720
Tatjana NovakovicDiscipline of Internal Medicine, Faculty of Medicine, University of Pristina, Anri Dinana bb, 38220 Kosovska Mitrovica, Serbia.
Milan FilipovicSurgery Department, Discipline of Plastic and Reconstructive Surgery, Faculty of Medicine, University of Pristina, Anri Dinana bb, 38220 Kosovska Mitrovica, Serbia.ORCID 0000-0001-9976-1472
Tatjana FilipovicDiscipline of Anatomy, Faculty of Medicine, University of Pristina, Anri Dinana bb, 38220 Kosovska Mitrovica, Serbia.
Zhao JingInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences (CACMS), Dongcheng District, Beijing 100700, China.
Marija DunjicDiscipline of Plastic and Reconstructive Surgery, Quince Medic Clinic, Bulevar Oslobodjenja 2, 11000 Belgrade, Serbia.
Miroslav M SovrlićDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-3300-6199
Sandra S KonstantinovićFaculty of Technology, University of Niš, 16000 Leskovac, Serbia.ORCID 0000-0002-3761-823X
Jelena S StanojevićFaculty of Technology, University of Niš, 16000 Leskovac, Serbia.ORCID 0000-0001-7923-0770
Milan D KostićFaculty of Technology, University of Niš, 16000 Leskovac, Serbia.
Stefano TuriniDepartment of Physical Medicine, Alma Mater Europaea (AMEU-ECM), Slovenska Ulica 17, 2000 Maribor, Slovenia.ORCID 0000-0003-4466-4530

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have examined bioactive constituents of

methodsThe analyzed study samples were profiled by GC/MS and GC/FID-based fatty-acid methyl ester analysis. An archived molecular-docking dataset was used to summarize structurally plausible interactions of six formulation-associated markers with eight melanoma-relevant or melanoma-adjacent targets and to present representative three-dimensional complexes. Because complete protocol metadata and co-crystallized-ligand redocking records were unavailable, the computational findings were interpreted descriptively. Neutral-red uptake assays assessed the 24 h viability of B16F10 melanoma cells and MRC-5 fibroblasts after exposure to each oil, the dual-oil formulation, or cisplatin. Four-parameter logistic models provided estimated IC

resultsThe dual-oil formulation yielded estimated IC

conclusionsThe findings define an exploratory chemical-computational-cellular framework and a preliminary formulation-level viability phenotype. They do not establish synergy, apoptosis, pathway modulation, therapeutic efficacy, or clinical safety. Independent multi-batch chemical confirmation, a fully documented and redocking-validated computational protocol, expanded melanoma and normal-skin cell panels, orthogonal functional assays, longer exposure periods, mechanistic validation, and subsequent in vivo studies are required.

Indexed as

B16F10dual-oil formulationexact Spearman correlationexploratory life-science studyFAMEGC-MSmalignant melanomamolecular dockingMRC-5neutral red uptake assayPinus sylvestrisPrunus dulcisthree-dimensional docking complexesα-pinene

Identifiers

PMID42653002
PMCPMC13515004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.